EICHOR
● Active Not Recruiting
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Condition: Biliary Tract Cancer · Metastatic Cancer · Advanced Cancer · Sponsor: Eli Lilly and Company
About this study
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (82)
| The University of Arizona Cancer Center | Tucson, Arizona, United States | — |
| UCSF Medical Center at Mission Bay | San Francisco, California, United States | — |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | — |
| University of Florida School of Medicine | Gainesville, Florida, United States | — |
| Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Washington University Medical School | City of Saint Peters, Missouri, United States | — |
| Washington University Medical School | Creve Coeur, Missouri, United States | — |
| Washington University Medical School | St Louis, Missouri, United States | — |
| Washington University Medical School | St Louis, Missouri, United States | — |
| Thomas Jefferson University | Philadelphia, Pennsylvania, United States | — |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | — |
| Florida Cancer Specialists | Nashville, Tennessee, United States | — |
+ 70 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02711553